United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening cardiovascular and infectious diseases and cancer. Our lead product, Remodulin, is approved in the U.S. and various countries around the world for both continuous subcutaneous and continuous intravenous infusion for the treatment of pulmonary arterial hypertension (PAH). In addition to prostacyclin analogs like Remodulin, United Therapeutics develops Glycobiological Antiviral Agents for the treatment of infectious diseases, such as Hepatitis C. For more information about United Therapeutics' pipeline, click here

To receive press releases, quarterly and annual SEC filings, please click here.

Current Press Releases

Feb 19, 2010
United Therapeutics Corporation Withdraws European Marketing Authorization Application for Tyvaso for the Treatment of Pulmonary Arterial Hypertension

Feb 16, 2010
United Therapeutics Corporation Reports 2009 Fourth Quarter and Annual Financial Results

more »

Events

May 3, 2010
Deutsche Bank 35th Annual Health Care Conference

May 26, 2010
Citi 2010 Annual Global Healthcare Conference

Sep 13, 2010
Morgan Stanley Global Healthcare Unplugged Conference

more »